Kalytera and Former Shareholders of Talent Biotechs Agree to Deferment of Milestone Payments
July 20, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, July 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it has entered...
Kalytera Announces Pre-IND Meeting Date with FDA
July 05, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, July 05, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that it will meet...
Kalytera Provides Update on its Lead Program in Prevention and Treatment of GVHD
June 21, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, June 21, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) and (OTCQB:KALTF) (the "Company" or "Kalytera") today provided an update on its lead...
Kalytera Reports First Quarter 2018 Financial Results
May 30, 2018 16:01 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, May 30, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today reported financial results for...
Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
May 15, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced the formation of...
Kalytera Issues CEO Letter to Shareholders
April 26, 2018 09:00 ET
|
Kalytera Therapeutics Inc.
Announces Meeting with FDA to Obtain Consent for Start of Phase 3 Pivotal Registration Study in Treatment of Acute GVHDAndProvides Corporate Update and Outlook for 2018 SAN FRANCISCO and TEL AVIV,...